CRSP vs HNGE: Which Stock Is the Better Buy?
CRISPR Therapeutics AG and Hinge Health, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CRSP vs HNGE, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| CRISPR Therapeutics AG (CRSP) | Hinge Health, Inc. (HNGE) | |
|---|---|---|
| Market cap | $4.9B | $5.0B |
| Revenue (latest FY) | $3.51M | $587.86M |
| Net income (latest FY) | $-581.60M | $-528.26M |
| Revenue growth (5y CAGR) | 37.3% | 41.7% |
| Net margin | -16569.8% | -89.9% |
| Return on equity | -30.3% | -139.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | No | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full CRSP vs HNGE breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CRSP's full financials → Open HNGE's full financials →More comparisons
Frequently asked questions
Which is bigger, CRSP or HNGE?
Hinge Health, Inc. is larger by market capitalization — $5.0B versus $4.9B.
Which grows faster, CRSP or HNGE?
Over the last five fiscal years, Hinge Health, Inc. grew revenue faster — 41.7%/yr versus 37.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
CRSP fundamentals → · HNGE fundamentals → · All 1,500+ companies → · Free screener →